News and Trends 11 Oct 2022 Gedea Biotech reports results from bacterial vaginosis trial Gedea Biotech has reported top-line results from a clinical study, NEFERTITI, of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). NEFERTITI is a placebo-controlled, double blind clinical trial performed in Sweden and UK in 150 patients. Treatment details The treatment is a vaginal tablet taken once daily for six […] October 11, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 11 Oct 2022 The biggest private biotech investments in September 2022 The companies Acelyrin, InnovaFeed and Arsenal Biosciences bagged the biggest biotech investments in September 2022, with insect protein and cell therapies attracting big funding rounds. Autumn is in full swing in the Northern Hemisphere. After a breather in August 2022, September saw the return of big fundraising activity for biotech companies. We’ve gathered the biggest […] October 11, 2022 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Muna Therapeutics gets $4.9M grant for Parkinson’s disease research Muna Therapeutics has been awarded a $4.9 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will be used to support ongoing preclinical research and development of novel, brain-exposed, small molecule potassium channel type 1.3 (Kv1.3) blockers to abrogate neuroinflammation driven by disease-associated microglia and enhance neuroprotection as a disease-modifying […] October 11, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Positive results from NMD Pharma myasthenia gravis trial NMD Pharma A/S has reported positive top-line results from its phase I/IIa clinical trial of NMD670, recently granted orphan drug designation by the FDA for treatment of myasthenia gravis (MG). NMD670 was safe and well tolerated in healthy volunteers and patients. Administration of single doses of NMD670 was associated with clinically significant improvements in the […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 Clinical Microbiomics expanding with €10M million investment Danish microbiome research company Clinical Microbiomics A/S has received €10 million ($9.7 million) in funding from Seventure Partners. Clinical Microbiomics, founded in 2015, is a microbiome analysis company, which includes work on clonal-level microbiome profiling. The company is working with food and consumer health companies and is supporting the pharmaceutical industry in phase 3 clinical […] October 11, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2022 Positive data indicates likely therapeutic effect of Alzheimer’s drug Positive phase 2a clinical data from an Alzheimer’s disease (AD) biomarker study, has been announced today (October 10). Actinogen Medical Limited shared the news that its study validates its planned program for Xanamem, a potential drug for the disease. The biomarker study was conducted in 72 patients with available blood biomarker samples from the prior […] October 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Fast track designation for Nanoscope Therapeutics’ retinitis pigmentosa treatment Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, says the U.S. Food and Drug Administration (FDA) has granted fast track designation (FTD) to MCO-010. MCO-010 is an ambient-light activatable multi-characteristic opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for the treatment of retinitis pigmentosa (RP) via intravitreal […] October 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 JW Therapeutics receives approval for relapsed or refractory follicular lymphoma drug China’s National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for JW Therapeutics’ anti-CD19 autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product relmacabtagene autoleucel injection. Also known as relma-cel, the product has the trade name Carteyva. It is used for the treatment of adult patients with follicular lymphoma that is […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Evonik and Phathom Pharmaceuticals partner on novel acid-blocker vonoprazan Evonik has entered into a long-term supply agreement with Phathom Pharmaceuticals, a U.S. biopharma company developing and commercializing new treatments for gastric acid-related diseases. Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, U.S., and Dossenheim, Germany. “The manufacture of vonoprazan requires multi-step syntheses involving complex chemistries. We are […] October 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Oct 2022 RadioMedix announces a $40 million series A financing for targeted alpha therapy platform A company committed to advancing treatments for rare and aggressive cancers has received a series A funding of $40 million. Clinical stage biotech, RadioMedix, Inc. announced the agreement with an entity related to Portland Investment Counsel Inc. (Portland), on Friday (October 7). RadioMedix is committed to the advancement of a targeted alpha therapy (TAT) pipeline […] October 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Trial starts for treatment of warm autoimmune hemolytic anemia China-based Hutchmed has started a phase 2/3 trial of sovleplenib in adults with a disorder called warm antibody autoimmune hemolytic anemia (wAIHA). The autoimmune disorder can lead to anemia and currently has limited treatment options. It causes premature destruction of healthy red blood cells and the rate of production of new cells in the bone […] October 10, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Oct 2022 Biocartis starts European commercialization of liver cancer test Biocartis Group NV has started the commercialization in Europe of the HepatoPredict test as a CE-IVD marked manual kit. The test, developed by Portuguese biotech company Ophiomics, is a prognostic diagnostic test that supports the decision of liver transplantation in patients with hepatocellular carcinoma (HCC). Herman Verrelst, chief executive officer of Biocartis, said: “We are […] October 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email